Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985021 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
A Phase 2 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02985021 is a Phase 2 study that was terminated before completion, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 2 participants.
The verdict
NCT02985021, a Phase 2 study, was terminated before completion, sponsored by Seattle Institute for Biomedical and Clinical Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985021
The ClinicalTrials.gov registry entry for NCT02985021 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT02985021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02985021 about?
NCT02985021 is a clinical study titled "Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies". In this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with docetaxel and carboplatin chemotherapy.
What is the current status of trial NCT02985021?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2016-11. Estimated completion is 2021-04.
What interventions are being tested in trial NCT02985021?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT02985021?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.